MaxCyte, Inc. filed an 8-K with the SEC on November 10, 2026, disclosing that it entered into a Securities Purchase Agreement on November 9, 2026, to acquire all outstanding equity interests of Akron BioProducts LLC from affiliates of Arcline Investment Management.

Key Highlights

  • Cash at closing: $105.0 million payable at closing, subject to customary adjustments, according to the filing.
  • Stock consideration: 20,639,733 shares of MaxCyte common stock, par value $0.01 per share, to be issued to the sellers at closing.
  • Deferred cash payments: $20.0 million in guaranteed, deferred cash payments, consisting of $10.0 million each payable on the first business day of 2028 and the first business day of 2029.
  • Expected closing: The company disclosed that closing is expected to occur before the end of 2026, subject to customary conditions including Hart-Scott-Rodino antitrust clearance.
  • Lock-up period: The stock consideration will be subject to a six-month lock-up following the closing.
  • No stockholder vote required: The filing states the transaction is not subject to a financing condition or the approval of the company's stockholders.
  • Q3 2026 results also announced: The company separately issued a press release on November 10, 2026, announcing financial results for the quarter ended September 30, 2026.

MaxCyte's Agreement to Acquire Akron BioProducts: Structure and Key Terms

According to the filing, MaxCyte, Inc. (NASDAQ:MXCT) entered into a Securities Purchase Agreement on November 9, 2026, with Ohio TopCo LP and Arcline Capital Partners A LP, together identified as the sellers and described as affiliates of Arcline Investment Management, along with other parties. Under the agreement, MaxCyte will indirectly acquire all outstanding equity interests of Akron BioProducts LLC. The total consideration has three components: $105.0 million in cash at closing, 20,639,733 shares of common stock, and $20.0 million in guaranteed deferred cash payments split equally across 2028 and 2029.

The filing states that the representations and warranties of the parties do not survive the closing, and that the company obtained a conditional binder for a buyer-side representations and warranties insurance policy, which the filing describes as providing the company's "sole recourse with respect to losses arising from breaches of the representations and warranties of the Sellers," except in cases of fraud by a seller. Closing conditions include expiration or termination of the applicable Hart-Scott-Rodino antitrust waiting period and Nasdaq approval for listing of the stock consideration. The agreement may be terminated if closing has not occurred within 120 days after the date of the Purchase Agreement, the filing disclosed.

The 20,639,733 shares comprising the stock consideration will be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, the filing stated, based in part on the sellers' representations that each is an "accredited investor" acquiring the shares for investment. At closing, the company and sellers will enter into a registration rights agreement covering the resale of the stock consideration. The filing also noted that the company issued a press release on November 10, 2026, announcing financial results for the quarter ended September 30, 2026, furnished as Exhibit 99.1.

What Was Disclosed

MaxCyte disclosed the terms of its agreement to acquire Akron BioProducts LLC, including a three-part consideration structure totaling $105.0 million in cash at closing, 20,639,733 common shares, and $20.0 million in deferred payments. The filing also referenced Q3 2026 financial results furnished separately.